专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050267190A1 Solid-state form of celecoxib having enhanced bioavailability 有权
公开(公告)号：US20050267190A1
公开(公告)日：2005-12-01
申请号：US11189659
申请日：2005-07-26
申请人： Michael Hageman , Xiaorong He , Tugrul Kararli , Lesley MacKin , Patricia Miyake , Brian Rohrs , Kevin Stefanski
发明人： Michael Hageman , Xiaorong He , Tugrul Kararli , Lesley MacKin , Patricia Miyake , Brian Rohrs , Kevin Stefanski
IPC分类号： C07D233/60 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/24 , A61K9/26 , A61K9/46 , A61K9/48 , A61K9/50 , A61K31/34 , A61K31/341 , A61K31/352 , A61K31/41 , A61K31/415 , A61K31/42 , A61K31/44 , A61K31/444 , A61K45/00 , A61K45/06 , A61K47/32 , A61K47/38 , A61P1/00 , A61P1/02 , A61P1/04 , A61P1/16 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P15/00 , A61P15/04 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/10 , A61P19/02 , A61P19/10 , A61P21/00 , A61P21/04 , A61P25/00 , A61P25/06 , A61P25/28 , A61P25/32 , A61P27/02 , A61P27/12 , A61P29/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/08 , A61P43/00 , C07D213/61 , C07D231/12 , C07D261/08 , C07D307/58 , C07D311/58
CPC分类号： C07D231/12 , A61K9/0007 , A61K9/14 , A61K9/145 , A61K9/146 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/209 , A61K9/5084 , A61K9/5161 , A61K31/415 , A61K31/635 , A61K47/34 , C07D213/61 , C07D261/08 , C07D307/58 , C07D311/58
摘要： The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.

2. 发明申请

US20220145681A1 Hinge Cover Assembly 有权
公开(公告)号：US20220145681A1
公开(公告)日：2022-05-12
申请号：US17521670
申请日：2021-11-08
申请人： Michael Hageman
发明人： Michael Hageman
IPC分类号： E05D11/00 , E05D11/06
摘要： This hinge cover assembly provides a cover member, stopping member, and fastener mechanism that work in tandem to stop the relative rotation of objects along an axis. This improved hinge cover assembly can be incorporated into multiple hinged object assemblies, including doors, windows, and cabinets.

3. 发明申请

US20060208796A1 Bias control for reducing amplifier power consumption and maintaining linearity 有权
标题翻译：降低放大器功耗并保持线性度的偏置控制
公开(公告)号：US20060208796A1
公开(公告)日：2006-09-21
申请号：US11085931
申请日：2005-03-21
申请人： Keith Nellis , Andre Metzger , Grant Small , Michael Hageman , Terry Shie , Kerry Burger
发明人： Keith Nellis , Andre Metzger , Grant Small , Michael Hageman , Terry Shie , Kerry Burger
IPC分类号： H03G3/20
CPC分类号： H03F1/30 , H03F1/0205 , H03F1/0261 , H03F1/32 , H03F3/195 , H03F2200/294 , H03F2200/318 , H03F2200/372 , H03F2200/411
摘要： A method and apparatus for biasing an amplifying device whereby the bias current tracks the input power or the power level of a control signal to thereby efficiently match the bias current with needs of the amplifying device. This method and apparatus overcomes the drawbacks of the prior art by biasing, not for maximum output power, but for the power level of the input signal or the control signal. In one embodiment a current conditioner operates in connection with the self adjusting biasing circuit to scale or adjust, potentially on an exponential basis, the biasing current for one or more amplifier stages. A cancellation current source may be configured within the bias circuit to cancel unneeded current to further minimize current consumption.
摘要翻译：一种用于偏置放大装置的方法和装置，由此偏置电流跟踪控制信号的输入功率或功率电平，从而根据放大装置的需要有效地匹配偏置电流。该方法和装置通过偏置而不是最大输出功率而是针对输入信号或控制信号的功率电平来克服现有技术的缺点。在一个实施例中，当前的调节器与自调整偏置电路结合起来，可能以指数的方式缩放或调整一个或多个放大器级的偏置电流。可以在偏置电路内配置消除电流源以消除不需要的电流以进一步最小化电流消耗。

4. 发明申请

US20070096810A1 Dual mode power amplifier 有权
标题翻译：双模功率放大器
公开(公告)号：US20070096810A1
公开(公告)日：2007-05-03
申请号：US11259006
申请日：2005-10-25
申请人： Michael Hageman , Dale Brandt , David Ripley
发明人： Michael Hageman , Dale Brandt , David Ripley
IPC分类号： H03G5/16
CPC分类号： H03G3/3042 , H03F1/0277 , H03F3/211 , H03F3/72 , H03F2200/222 , H03F2200/387 , H03F2203/7206 , H03F2203/7239
摘要： A power amplifier is configured to operate in a first gain mode and a second gain mode. A first power amplifier input stage has an input and an output. A second power amplifier input stage has an input and an output, where the output of the second power amplifier input stage is coupled to the output of the first power amplifier input stage. The first input stage is turned on in response to a first bias voltage in the first gain mode and the second input stage is turned on in response to a second bias voltage in the second gain mode. Alternatively, a first input stage and an intermediate stage can be switched off by turning off their respective bias voltages, and a second input stage can be switched on by turning on its respective bias voltage; the intermediate stage and the second input stage sharing a common output.
摘要翻译：功率放大器被配置为以第一增益模式和第二增益模式操作。第一功率放大器输入级具有输入和输出。第二功率放大器输入级具有输入和输出，其中第二功率放大器输入级的输出耦合到第一功率放大器输入级的输出。第一输入级响应于第一增益模式中的第一偏置电压而导通，并且第二输入级响应于第二增益模式中的第二偏置电压而导通。或者，可以通过关闭它们各自的偏置电压来关闭第一输入级和中间级，并且可以通过接通其各自的偏置电压来接通第二输入级; 中间级和第二输入级共享公共输出。

5. 发明申请

US20050156689A1 Method for tuning the center frequency of embedded microwave filters 有权
标题翻译：调整嵌入式微波滤波器中心频率的方法
公开(公告)号：US20050156689A1
公开(公告)日：2005-07-21
申请号：US10758095
申请日：2004-01-16
申请人： Michael Hageman , Cynthia Berry
发明人： Michael Hageman , Cynthia Berry
IPC分类号： H01P1/20 , H01P1/207 , H01P1/208 , H01P11/00
CPC分类号： H01P1/20 , H01P1/207 , H01P1/2088 , H01P11/007
摘要： A method of tuning the frequency response of filters embedded in or formed on a ceramic substrate, such as but not limited to a low temperature co-fired ceramic substrate (LTCC), by re-firing a previously fired LTCC substrate to a temperature which is greater by a predetermined, relatively small, amount than that of the temperature produced during the original firing profile of the substrate so as to change the dielectric constant of the substrate, and thus cause a desired shift in the filter's frequency response.
摘要翻译：通过将先前烧制的LTCC衬底重新烧结到温度为（℃）的温度，调节嵌入或形成在陶瓷衬底（例如但不限于低温共烧陶瓷衬底（LTCC））上的滤波器的频率响应的方法，比基板的原始焙烧曲线期间产生的温度预定的相对小的量更大，以便改变基板的介电常数，从而导致滤波器的频率响应的期望的偏移。

6. 发明申请

US20070202160A1 SOLID-STATE FORM OF CELECOXIB HAVING ENHANCED BIOAVAILABILITY 审中-公开
标题翻译：具有增强生物利用度的CELECOXIB的固态
公开(公告)号：US20070202160A1
公开(公告)日：2007-08-30
申请号：US11744603
申请日：2007-05-04
申请人： Michael Hageman , Xiaorong He , Tugrul Kararli , Lesley Mackin , Patricia Miyake , Brian Rohrs , Kevin Stefanski
发明人： Michael Hageman , Xiaorong He , Tugrul Kararli , Lesley Mackin , Patricia Miyake , Brian Rohrs , Kevin Stefanski
IPC分类号： A61K31/415 , A61K31/79 , A61K9/20 , A61K9/48
CPC分类号： C07D231/12 , A61K9/0007 , A61K9/14 , A61K9/145 , A61K9/146 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/209 , A61K9/5084 , A61K9/5161 , A61K31/415 , A61K31/635 , A61K47/34 , C07D213/61 , C07D261/08 , C07D307/58 , C07D311/58
摘要： The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.
摘要翻译：选择性环氧合酶-2抑制药塞来昔布以无定形形式提供。还提供了塞来昔布药物，其中塞来昔布以至少可检测量存在，作为无定形塞来昔布。还提供了塞来昔布结晶抑制剂复合物，其包含与一种或多种结晶抑制剂例如聚合物紧密结合的本发明的无定形塞来昔布或塞来昔布药物物质的颗粒。还提供了包含这样的塞来昔布结晶抑制剂复合物和一种或多种赋形剂的药物组合物。还提供了制备本发明的塞来昔布药物，本发明的塞来昔布结晶抑制剂复合物和本发明的药物组合物的无定形塞来昔布的制备方法。还提供了治疗受体中用环氧合酶-2抑制剂进行治疗的医学病症或病症的方法，包括以治疗有效量施用例如口服本发明组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式